FDA expands Zytiga’s use for late-stage breast cancer

Author(s):

On Dec. 10, the U.S. Food and Drug Administration expanded the approved use of Zytiga (abiraterone acetate) to treat men with metastatic castration-resistant prostate cancer before receiving chemotherapy. Read more.

LEAVE A REPLY

Please enter your comment!
Please enter your name here